Back to Home

Specialty Care Models

Expert articles and analysis related to specialty care models.

11 articles•Last 30 Days

AI Summary — Last 30 Days

Specialty VBC momentum is concentrating around oncology, orthopedics, and kidney care: new evaluation findings from Medicare’s Oncology Care Model show reduced chemotherapy use and lower Medicare spending for poor-prognosis cancers, reinforcing the strategic case for episode-based oncology models that reward guideline-concordant, patient-centered treatment rather than volume-driven infusion economics (AJMC). At the same time, market commentary around mandatory CMS orthopedic bundles and AI signals growing provider concern that the Trump administration’s CMS—under Administrator Dr. Mehmet Oz and CMMI Director Abe Sutton—may lean harder into compulsory specialty episodes, while integrated kidney care profitability for DaVita underscores that nephrology VBC is moving from policy experiment to scaled business model. For ACOs, payers, and health systems, the structural shift is clear: specialty care is becoming the next frontier for downside-risk management, requiring tighter referral governance, data-driven pathway adherence, and alignment with specialty groups whose economics may be disrupted by bundled or episode-based payment.

Related Articles

90ALN

Oncology Care Model Tied to Reduced Chemotherapy, Lower Medicare Spending in Poor-Prognosis Cancers

AJMCApr 27, 2026
90ALN

Hemp Product Use in Medicare: CMS Greenlights Pilot Program under the Substance Access Beneficiary Engagement Incentive

Foley & LardnerApr 9, 2026
80ALN

Early Integrated Kidney Care Profitability Could Be A Game Changer For DaVita (DVA) - simplywall.st

Early Integrated Kidney Care Profitability Could Be A Game Changer For DaVita (DVA)  simplywall.st

news.google.comApr 27, 2026
75ALN

Oncology Care Model Tied to Reduced Chemotherapy, Lower Medicare Spending in Poor-Prognosis Cancers - The American Journal of Managed Care® (AJMC®)

Oncology Care Model Tied to Reduced Chemotherapy, Lower Medicare Spending in Poor-Prognosis Cancers  The American Journal of Managed Care® (AJMC®)

news.google.comApr 27, 2026
75ALN

What Medicare’s Oncology Care Model Has Taught Us About Value-Based Care

What Medicare’s Oncology Care Model Has Taught Us About Value-Based Care  Harvard Medical School

Harvard Medical SchoolApr 27, 2026
45ALN

Oncology Care Model Tied to Reduced Chemotherapy, Lower Medicare Spending in Poor-Prognosis Cancers

Oncology Care Model Tied to Reduced Chemotherapy, Lower Medicare Spending in Poor-Prognosis Cancers  AJMC

AJMCApr 27, 2026
40ALN

STAT+: CMS, FDA team up to fast-track reimbursement for breakthrough devices

Federal regulators are proposing a new, faster Medicare coverage pathway for medical devices deemed by the FDA as breakthroughs.

STAT NewsApr 23, 2026
40ALN

STAT+: CMS proposes rolling back breakthrough device payment flexibilities

CMS is proposing to repeal a pathway that allows breakthrough devices to get supplementary payments.

STAT NewsApr 15, 2026
35ALN

Patient-Centered Oncology Care, Guidelines, and Expertise Drive Value in Practice: Seungjean Chai, MD

Patient-Centered Oncology Care, Guidelines, and Expertise Drive Value in Practice: Seungjean Chai, MD  The American Journal of Managed Care

The American Journal of Managed CareApr 30, 2026
30ALN

Advancing Innovation in Community Oncology Through Collaborative Care

Advancing Innovation in Community Oncology Through Collaborative Care  Pharmacy Times

Pharmacy TimesApr 28, 2026